Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Cytokinetics logo
CytokineticsCYTK
0.3×+0.1×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.1×0.0×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
0.0×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
0.2×+0.1×
Viking Therapeutics logo
Viking TherapeuticsVKTX
0.0×

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s debt-to-assets?
Edgewise Therapeutics, Inc. (EWTX) reported debt-to-assets of 0× in Q1 2026.
How has Edgewise Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Edgewise Therapeutics, Inc.'s debt-to-assets decreased by 27.0% year-over-year, from 0× to 0×.
What is the long-term trend for Edgewise Therapeutics, Inc.'s debt-to-assets?
Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s debt-to-assets has grown at a -15.7% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.